3/12/2013

Clinigen secured European rights to market Theravance's skin infection drug Vibativ, or telavancin, as a treatment for hospital-acquired pneumonia when other alternatives are not suitable. Vibativ acts against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. The deal entitles Theravance to $5 million upfront and royalties.

Related Summaries